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Abstract The nef gene is considered to play a crucial role in the
development of acquired immunodeficiency syndrome (AIDS). In
this study, we analyzed the sequence of nef quasispecies obtained
from replication-competent HIV-1 isolates from two Japanese
hemophiliac patients infected with HIV-1. At least 10 nef clones
were isolated at each time point and a total of 75 individual nef
quasispecies were sequenced. We observed a gradual increase in
genetic diversity of the nef gene over time. Among the various
functional regions of Nef protein, myristoylation site and the
central PXXP (SH3 ligand) motifs were well conserved. The
scattered regions responsible for downregulation of CD4 and
class I MHC were also conserved. These data suggest that these
functions of Nef may be involved throughout the disease process.
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1. Introduction
Nef is a myristoylated 27^30 kDa protein encoded by pri-
mate lentiviruses and is produced in abundance at an early
stage of the viral life cycle (reviewed in [1]). Nef is considered
to be an important determinant of acquired immunode¢ciency
syndrome (AIDS) pathogenesis [2^5]. For example, Nef was
shown to be necessary for maintaining high viral loads and
inducing AIDS-like disease in rhesus monkeys infected with
SIVmac239 [2]. Moreover, molecular studies with human
long-term non-progressors of human immunode¢ciency virus
type 1 (HIV-1) infection indicated that the intact nef gene
sequence was required for progression of AIDS [3^5].
A number of reports have demonstrated that various bio-
logical e¡ects of Nef were mediated through interaction with
various cellular factors. It has been demonstrated that the Src
homology region 3 (SH3) ligand region (PXXP) of Nef pro-
tein is involved in the association with Src-family proteins
(Src, Lyn, Hck, Lck and Fyn) and a¡ects signal transduction
pathways such as T-cell activation [6^11]. The N-terminal
myristoylation site and an acidic region have been implicated
in the viral infectivity in which Nef appears to facilitate re-
verse transcription in the incoming virion pre-integration
complex [12^16]. Nef has also been shown to downregulate
cell-surface CD4 protein by facilitating the endocytotic path-
way through its interaction with cellular factors such a cata-
lytic subunit of the vacuolar ATPase, NBP-1 [17^22].
In the present study, we have isolated the replication com-
petent HIV-1 isolates over time from two Japanese hemophil-
iacs patients infected with HIV-1 and analyzed the temporal
pro¢le of molecular evolution of the nef gene in vivo. We
observed that the complexity of nef sequence heterogeneity
was increased during the progression of HIV-1 infection.
We also found that some functional domains of Nef were
conserved in both patients.
2. Materials and methods
2.1. Patients material
Patients A and B are hemophiliacs who had been infected with
HIV-1 through a contaminated batch of factor VIII. The CD4 cell
counts, the CD4/CD8 ratio and the disease status of patients A and B
at each time of sample procurement are shown in Table 1. During the
periods when samples were isolated, patient A was treated with ddI
from May 1991 to January 1992 and 5P-azido-3P-deoxythymidine
(AZT) therapy from August 1992. Patient B was treated with ddI
and AZT therapy from April 1993.
2.2. Virus isolation
Virus isolation was performed according to the method previously
described [23,24]. Brie£y, peripheral blood mononuclear cells
(PBMCs) were Ficoll-separated from the heparinized blood and co-
cultivated with phytohaemagglutinin (PHA)-stimulated PBMCs from
HIV-1-negative healthy donors in RPMI 1640 medium containing
20% fetal calf serum, 0.25 U/ml recombinant interleukin-2 (Takeda
Chemical Industries, Osaka, Japan) and 50 U/ml of anti-human in-
terferon-K antibody (JCR Pharmaceuticals, Kobe, Japan). These in-
fected cells were maintained in culture for only a short period (3 to
4 days) before the cellular genomic DNA was separated. Virus stocks
were grown only once in PHA-stimulated PBMC cultures.
2.3. Polymerase chain reaction (PCR) ampli¢cation of the nef gene
In order to purify the cellular genomic DNA, the HIV-1-infected
PBMCs were resuspended in digestion bu¡er (100 mM NaCl, 10 mM
Tris-HCl, pH 8.0, 25 mM EDTA, 0.5% SDS, 0.1 mg/ml proteinase
K), incubated at 50‡C for 18 h, extracted by phenol-chloroform, and
then ethanol-precipitated according to the standard method. The pu-
ri¢ed DNA from PBMC cultures infected with each HIV-1 isolate was
served as the template for PCR. The HIV-1 nef region was ampli¢ed
by using Expand High Fidelity PCR System (Roche Diagnostics,
Mannheim, Germany) according to the manufacturer’s recommenda-
tions. PCR primer pairs were designed in order to cover most of the
heterologous nef gene populations according to the HIV-1 sequences
registered in GenBank. Among the four di¡erent primer sets we ex-
amined for nef gene ampli¢cation, the following two primer sets gave
good ampli¢cation of the nef gene in most of the samples. The primer
sequences we chose were as follows: primer pair 1: 5Pnef1(5P-ATAG-
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CAGTAGCTGAGGGGACAGATAG-3P) and 3Pnef1 (5P-CTGGTC-
TAACCAGAGCCCAGTACAGGCA-3P) ; primer pair 2: 5Pnef2 (5P-
CACATACCTAGAAGAATAAGACAGGGCT-3P) and 3Pnef1.
2.4. Cloning and sequencing
PCR mixture was run on 1.2% low melting temperature agarose
(FMC BioProducts, ME, USA) and the 847 bp DNA fragment (using
the primer set 1) and the 812 bp DNA fragment (using the primer set
2) were recovered using GENECLEAN kit (BIO 101, CA, USA). The
puri¢ed DNA was subsequently ligated into a PCR-blunt vector using
the Zero blunt PCR cloning kit (Invitrogen, CA, USA). For each
virus isolate at each time point, at least 10 individual plasmid clones
containing the nef gene were sequenced using the Bigdye terminator
cycle sequencing reaction kit (Perkin Elmer, CA, USA) and ABI
PRISM 310 Genetic Analyzer (Perkin Elmer). Standard M13 univer-
sal and reverse primers as well as internal nef-speci¢c primers (5Pnef3,
5P-GGTTTTCCAGTCAGACCT-3P ; 3Pnef2, 5P-CTCTCCTTCATT-
GGCCT-3P) were used as sequencing primers. The nucleotide se-
quence data in this paper had been submitted to the DDBJ, EMBL
and GenBank databases and were assigned to the accession numbers:
AB012809^AB012820, AB012821^AB012837, AB012839^AB012842
and AB026222^AB026247.
2.5. Analysis of the sequence data
Phylogenetic analyses were performed to investigate the similarity
among the isolates in this study and previously reported HIV-1
strains, HIV-1SF2 [25] and HIV-1 LAI [26]. Using the computer pro-
gram ODEN version 1.1.1 [27], the number of nucleotide substitutions
per site and the genetic distances for all these isolates were estimated
by the six-parameter method [28,29]. Based on these values, phyloge-
netic trees were constructed by the neighbor-joining method [30]. To
con¢rm the reliability of the phylogenetic tree, bootstrap resampling
tests were performed 1000 times [31]. Sequence diversities (%) between
pairs of DNA and amino acid sequences were calculated using
DNADIST program and PROTDIST program, respectively, of the
PHYLIP 3.5c program package [32].
3. Results and discussion
3.1. Sequence analysis of the Nef protein derived from patients
A and B
Table 1 shows the patient pro¢le at the time when the HIV-
1 nef gene was obtained. At each time for each patient we
isolated and sequenced at least 10 individual clones. From
patient A, we obtained a total of 45 sequences. Among these
clones, there were 37 distinct nef DNA clones. Since some of
the clones shared amino acid sequences, although di¡ered for
their DNA sequences, a total of 34 distinct Nef amino acid
sequences were obtained. From patient B, we obtained a total
of 26 distinct nef DNA sequences and 23 distinct Nef amino
acid sequences.
The aligned protein sequence data sets obtained from the
replication competent HIV-1 isolates are demonstrated in Fig.
1. Amino acid sequence variation was found scattered
throughout Nef protein and even from the visual inspection
it was noted that the amino acid sequence heterogeneity be-
came greater over time in each patient. Potential functional
protein domains indicated by previous studies [19,20,33^36]
are indicated in the top of this Fig. 1 (the details will be
discussed in the later part of this report).
In each patient, there were some clones with the same ami-
no acid sequence (for example with patient A, A-I-1, A-I-2
and A-I-3 had the same amino acid sequence although their
DNA sequences were di¡erent; there were some other clones
with the same amino acid sequence although they were iso-
lated in di¡erent time points such as A-I-4, A-I-5 and A-II-6).
The identical clones, containing the same DNA sequence,
were obtained (such as A-I-6 (2 identical clones) and A-II-1
(4 identical clones)). However, no identical clones were found
among the di¡erent time points. In patient B, six clones
shared the same amino acid sequence (B-1-1(3), 2, 3 and 4),
among which three clones shared even the same DNA se-
quence (B-I-1(3)). In both patients, duplication of 12 to 27
nucleotide were found in a restricted region known as ‘varia-
ble region’ (in clones A-II-2, A-II-3, A-II-4, A-II-5, A-IV-3,
A-IV-4, A-IV-5, B-III-5(2) and B-III-8) [28]. Frame-shift mu-
tants were noted in some clones (7 out of 45 clones in patient
A and 6 out of 25 clones in patient B) and a mutant with
premature termination was noted in one clone (B-I-8, patient
B) as previously reported [3,4,33]. It was noted that B-I-5, in
which additional nucleotide ‘T’ was inserted at the nucleotide
position 227 of B-I-1(3) and thus resulted in an extensive
frame-shift mutation.
3.2. Genetic diversity of nef gene over time during the disease
progression
The nucleotide sequence diversities of the nef gene in both
patients were evaluated using DNADIST program. As dem-
onstrated in Fig. 2, the nef quasispecies increased in complex-
ity over time. The temporal increase of complexity in patient
A might be due to the emergence of other HIV-1 quasispecies
with duplication at the ‘variable region’ in the 5P region
(clones A-II-2, A-II-3, A-II-4 and A-II-5) and that with +1
frameshift at nucleotide position 317 (clones A-II-1 and A-II-
7) (Fig. 1). During the disease progression the genetic diversity
of each nef quasispecies reached the average divergences of
7.33% and 7.34% at the latest stage of HIV-1 infection for
patients A and B, respectively (Fig. 2). It was noted that the
sequence diversity was rising even before the clinical criteria
for diagnosis of AIDS was ful¢lled.
To further examine the overall variability of the nef DNA
sequence, phylogenetic trees were constructed using ODEN
software (version 1.1.1) [27,29]. As demonstrated in Fig. 3,
nef sequences obtained from the late clinical stages of patients
(marked by open boxes) do not form distinct clusters, which is
consistent with the results shown in Fig. 2. In contrast, nef
sequences obtained from earlier stages form multiple distinct
clusters (for example, A-I, A-II, and A-III quasispecies are
separately grouped in patient A) as previously indicated by
Plikat et al [35]. In both patients, the nucleotide sequence
diversity within the same quasispecies obtained from the ear-
lier stages of the disease had a limited heterogeneity, whereas
that from the later stage (A-IV and B-III quasispecies ob-
tained at the CDC classi¢cation stage 4) showed more exten-
sive heterogeneity. The extents of genetic diversity of the nef
gene observed in this study were similar to that obtained in
the previous reports for nef [33] and env [37,38] genes by
others.
C
Fig. 1. Nef amino acid sequences corresponding to HIV-1 nef clones obtained from patients A and B. Amino acid sequences are aligned with
clones A-I-12 and B-I-1 as standards. Gaps (-) are introduced to maximize homology. Asterisks (*), position of premature termination. Slashes
(/), deletion. Dots (.), identical amino acids. LTR, long terminal repeat. PPT, polypurine tract.
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3.3. Conservation of functional Nef domains during disease
progression
To examine whether positive selection is operating on the
certain regions of nef gene in vivo, we evaluated the domain-
speci¢c sequence diversity both at the DNA and the protein
levels (Fig. 4). Among various functional Nef domains de¢ned
by others, we found that the N-terminal myristoylation site
and the SH3-binding motif (PxxP)3 were well conserved in
both patients (Fig. 1, 4). It was noted that genetic diversities
of these regions at the protein level were much lower than
those at the DNA level, especially for (PXXP)3 which showed
complete amino acid sequence conservation in patient B. We
also found that in these regions most of the substitutions were
synonymous in spite of the fact that there was increasing
sequence diversity at the DNA level over time (Fig. 4). The
potential thioesterase binding region (between 111 and 126
amino acids) was also conserved, although to a lesser extent
[36]. These data suggest that the conserved Nef regions, thus
their relevant biological functions, may be required for main-
taining the virus to be competent for replication throughout
the course of infection in vivo and that these functions may be
required for the viral pathogenesis [2^5]. In spite of extensive
investigations of the nef sequence heterogeneity, selective con-
servation of these regions during the disease progression in
vivo has not been previously noted [33^35,39]. Since in these
studies the nef gene was ampli¢ed directly from the patient
plasma or the infected cells, it is likely that these nef sequences
did not represent the replication-competent virus [40^43].
Although these defective viruses may kill the infected cells,
they do not produce progeny virions and thus do not contrib-
ute to the disease progression.
Myristoylation of Nef protein at its N-terminus has been
Fig. 2. Temporal increase of sequence diversity in the nef gene. Se-
quence diversity was calculated based on the distance for each pair
of clones using the DNADIST program. Average diversity of pa-
tient A (b) and B (R) at each time of virus isolation was indicated.
The abscissa indicates the time scale (in months) with the time of
¢rst virus isolation as a starting point.
Fig. 3. Phylogenetic tree of the HIV-1 nef DNA sequences. The relationships among 45 clones of patient A (A) and 30 clones of patient B (B)
are demonstrated. The tree was constructed by the neighbor-joining method using a software ODEN version 1.1.1 [27]. One thousand bootstrap
replications were performed. Bootstrap probabilities for major clusters are shown by percentages (%). Clones obtained from the late clinical
stage (CDC classi¢cation 4) of these patients are identi¢ed by open boxes.
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implicated in its cytoplasmic membrane association [44] and
in the viral pathogenicity [45]. Requirement of the N-terminal
myristoylation, thus its membrane localization, has been in-
dicated in the Nef-induced CD4 and class I MHC down reg-
ulation [12,13], T-cell signaling [14], and viral infectivity [15].
More importantly, Aldrovandi et al. [45] have recently dem-
onstrated that the sole aberration of the myristoylation site
resulted in the great loss of viral pathogenicity in vivo using
SCID-hu mouse model in which human thymic tissue was
implanted in SCID mice.
Nef has been shown to bind to SH3 domains of a subset of
Src family tyrosine kinases [6^8] and a cellular serine/threo-
nine kinase related to a p21 kinase (PAK), designated Nef-
associated kinase [9,10] through the highly conserved central
SH3 ligand motifs (PXXP)3. Although the pathophysiological
relevance of these protein-protein interactions remains to be
established, it was suggested that Nef might interfere with T-
cell signaling through its interaction with these kinase mole-
cules. It is possible that juxtaposing these signal-transducing
kinases that are not normally in contact, Nef may modulate
the activation status of the cell. It is also possible that the
reported Nef functions in interference of cell signaling may
be secondary to other Nef functions such as class I MHC
downregulation [46].
3.4. Conservation of the multiple Nef regions responsible for
downregulation of CD4 and class I MHC
Although initial reports have attributed the D/EX-
Fig. 4. DNA and amino acid sequence heterogeneity among the HIV-1 nef clones obtained from the serial samples of two Japanese AIDS pa-
tients (cases A and B). Functional domains indicated are according to the previous studies [19,20,33^35]. Sequence diversities were calculated
by DNADIST and PROTDIST program of the PHYLIP 3.5c program package [29]. Calculation was performed with the nef quasispecies at
each time of virus isolation in each patient. Patient A: (E) clones obtained in 1989.1, (lightly dotted square) 1989.5, (darkly dotted square)
1990.8. (F) 1994.8. Patient B: (E) clones obtained in 1990.7, (lightly dotted square) 1991.2, (darkly dotted square) 1994.9. See the text for the
details of comparison.
Table 1
Clinical course of hemophiliac patients studied and HIV-1 virus isolates
Date of virus
Isolation
CDC classi¢cation CD4 count (per Wl) CD4/CD8 ratio Anti-HIV treatment Designation of nef clones
Patient A:
1989.1 2 305 0.28 none A-I-1 to A-I-13
1989.5 2 230 0.22 none A-II-1 to A-II-7
1990.8 2 116 0.17 none A-III-1 to A-III-10
1994.8 4 5 N/A AZT (92.8 to 94.2) A-IV-1 to A-IV-7
ddC (94.2 to 94.7)
AZT (94.7 to 94.8)
Patient B:
1990.7 2 585 0.80 none B-I-1 to B-I-8
1991.2 2 660 0.68 none B-II-1 to B-II-10
1994.9 4 60 N/A AZT (94.4 to 94.9) B-III-1 to B-III-9
Clone designation is given on the right, indicating the patient, the time point of virus isolation and the clone number. N/A: not available.
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XXXLL165 region responsible for CD4 downregulation [20], it
was not conserved in our study. However, recent studies have
identi¢ed more restricted amino acid residues, located sepa-
rately in multiple locations in Nef protein, are responsible for
CD4 downregulation. For example, an NMR study by Grze-
siek, et al., [10] implicated that the residues WLE59, GGL97,
R106 and L110 of Nef were involved in binding to CD4, which
was recently con¢rmed by site-directed mutagenesis [21]. In
addition, Piguet et al. [22] has recently identi¢ed EE155 and
LL165 to be responsible for the Nef-mediated CD4 downregu-
lation through its interaction with the L-subunit of COPI
coatmer and adapter protein complex of clathrin-coated
pits, respectively. We found that most of these sequences
were well conserved in both patients.
Similarly, the Nef regions implicated in downregulation of
class I MHC were also conserved. Greenberg et al [46] have
reported that the N-terminal acidic region and the (PXXP)3
motifs were involved in downregulation of class I MHC. Sim-
ilarly, the N-terminal acidic region (at positions 62^65), also
implicated in class I MHC downregulation, was conserved for
its acidic nature since the observed substitutions were among
acidic amino acid residues.
3.5. Concluding remarks
We have initiated this study to verify the previous func-
tional studies of Nef using in vitro systems reported by others,
since some functions of Nef delineated in vitro may not be
relevant for in vivo pathogenicity. We have analyzed the nef
gene sequences originated only from replication competent
HIV-1 isolates in order to avoid sequence information derived
from defective HIV-1 clones that are no longer responsible for
pathogenesis. Our ¢ndings of the conservation of certain func-
tional regions in Nef suggested that Nef is involved in AIDS
pathogenesis through downregulation of CD4 and class I
MHC and possibly through interference of T-cell activation
signaling.
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